The classes of bDMARDs currently utilized in RA treatment mainly target tumor necrosis factor-alpha (TNF) inhibition, interleukin-6 (IL-6), CD-20 depletion, and IL1 [228]. The gene discussed is IL6; the disease is rheumatoid arthritis.